Collectionner le produit
Détails du produit
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Raji/Human CD19 & CD20 Double Knockout Stable Cell Line was generated from Raji cells through targeted knockout of human CD19 (Gene ID: 930) and CD20 (Gene ID: 931). The expression level of human CD19 and CD20 were confirmed by flow cytometry. Mutated sequences of human CD19 and CD20 produced by non homologous end joining (NHEJ) were confirmed through genomic sequencing.
Application
• Useful for cell-based CD19 and CD20 target-specific analysis
• Screening for agents targeting CD19 and CD20, including antibodies and CAR-T cell therapies.
Growth Properties
suspension
Selection Marker
NA
Complete Growth Medium
RPMI-1640 + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
Receptor Assay
Expression analysis of human CD19 on Raji/Human CD19 & CD20 Double Knockout Stable Cell Line by FACS.
Cell surface staining was performed on Raji/Human CD19 & CD20 Double Knockout Stable Cell Line using PE-labeled anti-human CD19 antibody. The Raji cells were stained with PE-labeled anti-human CD19 antibody as the positive control cell. The Raji cells were stained with PE-labeled isotype control antibody as the negative control cell.Protocol
Expression analysis of human CD20 on Raji/Human CD19 & CD20 Double Knockout Stable Cell Line by FACS.
Cell surface staining was performed on Raji/Human CD19 & CD20 Double Knockout Stable Cell Line using FITC-labeled anti-human CD20 antibody. The Raji cells were stained with FITC-labeled anti-human CD20 antibody as the positive control cell. The Raji cells were stained with FITC-labeled isotype control antibody as the negative control cell.Protocol
Sequencing Analysis
Genomic Sequencing of human CD19 in the Raji/Human CD19 & CD20 Double Knockout Stable Cell Line.
Sanger sequencing was used for mutation analysis of human CD19. The sequencing results demonstrated that frameshift mutations were generated in the human CD19 gene in the Raji/Human CD19 & CD20 Double Knockout Stable Cell Line.
Genomic Sequencing of human CD20 in the Raji/Human CD19 & CD20 Double Knockout Stable Cell Line.
Sanger sequencing was used for mutation analysis of human CD20. The sequencing results demonstrated that frameshift mutations were generated in the human CD20 gene in the Raji/Human CD19 & CD20 Double Knockout Stable Cell Line.
Avis des utilisateurs Publier un commentaire
Déclaration importante
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Contact Us
Drug Candidate Licensing
